FDA advisory panels plan to meet in September on anemia drugs made by Johnson & Johnson and Amgen to look at safety issues, including potential fatalities. One panel is to examine J&J's Procrit for patients with anemia caused by kidney failure, the other Amgen's Epogen and Aranesp, both for the same indication.

Related Summaries